Skip to main content
SpringerLink
Log in

Botulinum toxin in the management of dystonia

  • Movement Disorders
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Lesser RP, Fahn S:Dystonia: a disorder often misdiagnosed as a conversion reaction.Am J Psychiatry 1978, 135:349–352.

    PubMed  CAS  Google Scholar 

  2. Ozelius LJ, Hewett JW, Page CE, et al.:The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.Nat Genet 1997, 17:40–48.

    Article  PubMed  CAS  Google Scholar 

  3. Greene P, Shale H, Fahn S:Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.Mov Disord 1988, 3:46–60.

    Article  PubMed  CAS  Google Scholar 

  4. Jankovic J, Brin MF:Therapeutic uses of botulinum toxin.N Engl J Med 1991, 324:1186–1194.

    PubMed  CAS  Google Scholar 

  5. Lew MF, Adornato BT, Duane DD, et al.:Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.Neurology 1997, 49:701–707.

    PubMed  CAS  Google Scholar 

  6. Jankovic J, Orman J:Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.Neurology 1987, 37:616–623.

    PubMed  CAS  Google Scholar 

  7. Brans JW, Lindeboom R, Snoek JW, et al.:Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.Neurology 1996, 46:1066–1072.

    PubMed  CAS  Google Scholar 

  8. Of major importance Comella CL, Jankovic J, Shannon KM, et al.:Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 2005, 65:1423–1429. Forst tandomized, blinded, head-to-head comparative study between toxin serotypes.

    Article  PubMed  CAS  Google Scholar 

  9. Of importance Pappert EJ, Leong MS, Royal MA:Botulinum toxin type B compared with type A in the treatment of toxin-naive patients with cervical dystonia: results from a randomized, double-blind study.Neurology 2006, 66(Suppl 2):252. Randomized, blinded, head-to-head comparison of botulinum toxins type A and B, currently vailable in abstract form.

    Google Scholar 

  10. Comella CL, Buchman AS, Tanner CM, et al.:Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.Neurology 1992, 42:878–882.

    PubMed  CAS  Google Scholar 

  11. Barbano RL:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful.Muscle Nerve 2001, 24:1567–1568.

    Article  PubMed  CAS  Google Scholar 

  12. Jankovic J:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required.Muscle Nerve 2001, 24:1568–1570.

    Article  PubMed  CAS  Google Scholar 

  13. Borodic GE, Pearce LB, Smith K, et al.:Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle.Head Neck 1992, 14:33–37.

    Article  PubMed  CAS  Google Scholar 

  14. Jankovic J, Schwartz K:Botulinum toxin injections for cervical dystonia.Neurology 1990, 40:277–280.

    PubMed  CAS  Google Scholar 

  15. Berman B, Seeberger L, Kumar R:Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.Mov Disord 2005, 20:233–237.

    Article  PubMed  Google Scholar 

  16. Haussermann P, Marczoch S, Klinger C, et al.:Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.Mov Disord 2004, 19:303–308.

    Article  PubMed  Google Scholar 

  17. Jankovic J, Hunter C, Dolimbek BZ, et al.:Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.Neurology 2006, 67:2233–2235.

    Article  PubMed  CAS  Google Scholar 

  18. Jankovic J, Vuong KD, Ahsan J:Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology 2003, 60:1186–1188.

    PubMed  CAS  Google Scholar 

  19. Brin MF, Lew MF, Adler CH, et al.Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 1999, 53:1431–1438.

    PubMed  CAS  Google Scholar 

  20. Factor SA, Molho ES, Evans S, Feustel PJ:Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.Mov Disord 2005, 20:1152–1160.

    Article  PubMed  Google Scholar 

  21. Blackie JD, Lees AJ:Botulinum toxin treatment in spasmodic torticollis.J Neurol Neurosurg Psychiatry 1990, 53:640–643.

    Article  PubMed  CAS  Google Scholar 

  22. Truong D, Duane DD, Jankovic J, et al.:Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebocontrolled study.Mov Disord 2005, 20:783–791.

    Article  PubMed  Google Scholar 

  23. Ranoux D, Gury C, Fondarai J, et al.:Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.J Neurol Neurosurg Psychiatry 2002, 72:459–462.

    PubMed  CAS  Google Scholar 

  24. Ben Simon GJ, McCann JD:Benign essential blepharospasm.Int Ophthalmol Clin 2005, 45:49–75.

    Article  PubMed  Google Scholar 

  25. Kerty E, Eidal K:Apraxia of eyelid opening: clinical features and therapy.Eur J Ophthalmol 2006, 16:204–208.

    PubMed  CAS  Google Scholar 

  26. Pang AL, O’Day J:Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?Clin Experiment Ophthalmol 2006, 34:441–444.

    Article  PubMed  Google Scholar 

  27. Silveira-Moriyama L, Goncalves LR, Chien HF, et al.:Botulinum toxin A in the treatment of blepharospasm: a 10-year experience.Arq Neuropsiquiatr 2005, 63:221–224.

    PubMed  Google Scholar 

  28. Truong DD, Jost WH:Botulinum toxin: clinical use.Parkinsonism Relat Disord 2006, 12:331–355.

    Article  PubMed  Google Scholar 

  29. Bhidayasiri R, Cardoso F, Truong DD:Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:21–29.

    Article  PubMed  Google Scholar 

  30. Tan EK, Jankovic J:Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology 1999, 53:2102–2107.

    PubMed  CAS  Google Scholar 

  31. Bhattacharyya N, Tarsy D:Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.Arch Otolaryngol Head Neck Surg 2001, 127:389–392.

    PubMed  CAS  Google Scholar 

  32. Adler CH, Factor SA, Brin M, et al.:Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.Mov Disord 2002, 17:158–161.

    Article  PubMed  Google Scholar 

  33. Blitzer A, Sulica L:Botulinum toxin: basic science and clinical uses in otolaryngology.Laryngoscope 2001, 111:218–226.

    Article  PubMed  CAS  Google Scholar 

  34. Truong DD, Bhidayasiri R:Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:36–41.

    Article  PubMed  Google Scholar 

  35. Blitzer A, Brin MF, Stewart CF:Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.Laryngoscope 1998, 108:1435–1441.

    Article  PubMed  CAS  Google Scholar 

  36. Smith ME, Ford CN:Resistance to botulinum toxin injections for spasmodic dysphonia.Arch Otolaryngol Head Neck Surg 2000, 126:533–535.

    PubMed  CAS  Google Scholar 

  37. Pullman SL, Greene P, Fahn S, et al.:Approach to the treatment of limb disorders with botulinum toxin A.Arch Neurol 1996, 53:617–624.

    PubMed  CAS  Google Scholar 

  38. Gordon NS:Focal dystonia, with special reference to writer’s cramp.Int J Clin Pract 2005, 59:1088–1090.

    Article  PubMed  CAS  Google Scholar 

  39. Das CP, Dressler D, Hallett M:Botulinum toxin therapy of writer’s cramp.Eur J Neurol 2006, 13:55–59.

    Article  PubMed  Google Scholar 

  40. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al.:Botulinum toxin for writer’s cramp: a randomised, placebocontrolled trial and one year follow up.J Neurol Neurosurg Psychiatry 2007, 78:264–270.

    Article  PubMed  CAS  Google Scholar 

  41. Hsiung GY, Das SK, Ranawaya R, et al.:Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord 2002, 17:1288–1293.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Parkinson’s Disease and Movement Disorders Center of Albany Medical Center, 47 New Scotland Avenue, 12208, Albany, NY, USA

    Eric S. Molho MD

Authors
  1. Omar D. Cardona-Garcia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald S. Higgins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric S. Molho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric S. Molho MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cardona-Garcia, O.D., Higgins, D.S. & Molho, E.S. Botulinum toxin in the management of dystonia. Curr Treat Options Neurol 9, 224–233 (2007). https://doi.org/10.1007/BF02938412

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02938412

Keywords

Search

Navigation